Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OraPharma (acquired by JNJ)

Request full access

And commercializes products that help improve and maintain oral health

Bridgewater, United StatesFounded 1996Biotech & Life Sciences

About OraPharma (acquired by JNJ)

OraPharma is a specialty pharmaceutical company focused on developing and commercializing therapeutics for the oral health market, specifically targeting dental professionals and their patients. The company was founded in 1996 by Michael Kishbauch.

The company's flagship product is ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) procedures for the treatment of adult periodontitis. This product utilizes a patented microsphere delivery technology to provide a time-released antibiotic directly to the site of infection in the gums. Beyond ARESTIN®, OraPharma's portfolio includes the OSSIX® line of regenerative solutions for oral surgery and the OraFit™ custom clear dental aligner system for correcting malocclusion. The business model centers on selling these specialized products directly to dental professionals, including dentists, hygienists, oral surgeons, and periodontists. The company supports this with a large specialized pharmaceutical sales force and educational initiatives, such as the ARESTIN Student Access Program, which provides training and resources to dental and dental hygiene schools.

OraPharma has a notable corporate history involving multiple acquisitions. In November 2002, Johnson & Johnson announced its agreement to acquire OraPharma for approximately $85 million, a deal that was completed in early 2003. Subsequently, in 2011, the private equity firm Water Street Healthcare Partners acquired OraPharma from Johnson & Johnson with plans to expand its portfolio. This led to another acquisition in June 2012, when Valeant Pharmaceuticals International (now Bausch Health Companies Inc.) purchased OraPharma for approximately $312 million, plus potential milestone payments. Today, OraPharma operates as the oral health care business of Bausch Health, continuing to partner with dental service organizations and professionals nationwide.

Source: Dealroom company data

OraPharma (acquired by JNJ) in the Bridgewater ecosystem

Live from Dealroom

The OraPharma (acquired by JNJ) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later5 investors entered at this stage

  • HealthCap
  • Oak Investment
  • Canaan
  • TL Ventures
  • Domain Associates
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States97.4%
🇰🇷 South Korea1.3%
🇨🇦 Canada1.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OraPharma (acquired by JNJ) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OraPharma (acquired by JNJ) on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.